


**DIVI'S LABORATORIES LIMITED**

**UNAUDITED FINANCIAL RESULTS (STANDALONE)  
FOR THE QUARTER ENDED 30<sup>TH</sup> JUNE, 2014**

(₹ in Lakhs)

Sl No.	Particulars	STANDALONE			
		Unaudited			Audited
		Quarter ended 30.06.2014	Quarter ended 31.03.2014	Quarter ended 30.06.2013	Year Ended 31.03.2014
(1)	(2)	(3)	(4)	(5)	
1	<b>Income from operations</b>				
	(a) Net Sales/Income from operations (Net of Excise Duty)	<b>63976</b>	73801	51588	250718
	(b) Other Operating Income	<b>290</b>	259	127	679
	<b>Total Income from operations (net)</b>	<b>64266</b>	74060	51715	251397
2	<u>Expenditure:</u>				
	a. Cost of materials consumed	<b>29672</b>	22178	28389	103189
	b. Purchases of stock-in-trade	<b>0</b>	0	0	0
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	<b>(4778)</b>	8247	(10640)	(11375)
	d. Employee benefits expense	<b>6018</b>	5915	5303	22543
	e. Depreciation and amortization expense	<b>3326</b>	2539	2088	9206
	f. Other Expenses	<b>9837</b>	11538	8945	35154
	Total Expenses	<b>44075</b>	50417	34085	158717
3	Profit from Operations before Other Income, Interest & Exceptional Items (1-2)	<b>20191</b>	23643	17630	92680
4	Other Income	<b>1269</b>	938	5342	8390
5	Profit from ordinary activities before finance costs & exceptional Items (3+4)	<b>21460</b>	24581	22972	101070
6	Finance Costs	<b>36</b>	91	41	206
7	Profit from ordinary activities after finance costs but before exceptional Items (5-6)	<b>21424</b>	24490	22931	100864
8	Exceptional items	<b>0</b>	0	0	0
9	<u>Profit from ordinary activities before Tax (7-8)</u>	<b>21424</b>	24490	22931	100864
10	Tax Expense:	<b>4631</b>	5184	5460	21692
11	<u>Net Profit from ordinary activities after Tax: (9-10)</u>	<b>16793</b>	19306	17471	79172
12	Extra-ordinary items (net of tax expense)	<b>0</b>	0	0	0
13	Net Profit (+)/Loss(-) for the period (11-12)	<b>16793</b>	19306	17471	79172
14	Share of profit / (loss) of associates	<b>0</b>	0	0	0
15	Minority Interest	<b>0</b>	0	0	0


16	Net Profit (+)/Loss(-) after taxes, minority interest and share of profit/ (loss) of associates (13+14+15)	16793	19306	17471	79172
17	Paid-up Equity Share Capital (Face Value : Rs.2 per share)	2655	2655	2655	2655
18	Reserves excluding revaluation reserves as per balance sheet of previous accounting year				300787
19.i	Earnings per Share (before extraordinary items) (of Rs.2/- each) (not annualized):				
	a) Basic	12.65	14.54	13.16	59.65
	b) Diluted	12.65	14.54	13.16	59.65
19.ii	Earnings per Share (after extraordinary items) (of Rs.2/- each) (not annualized):				
	a) Basic	12.65	14.54	13.16	59.65
	b) Diluted	12.65	14.54	13.16	59.65

A	PARTICULARS OF SHAREHOLDING				
1	Public shareholding - No. of shares - Percentage of shareholding	63603674 47.92%	63603674 47.92%	63512190 47.85%	63603674 47.92%
2	Promoters and promoter group shareholding: a) pledged / encumbered b) non-encumbered: No. of shares Percentage of shares (as a % of the total shareholding of the promoter group) Percentage of shares (as a % of the total share capital of the company)	Nil 69130616 100% 52.08%	Nil 69130616 100% 52.08%	Nil 69222100 100% 52.15%	Nil 69130616 100% 52.08%

	Particulars	Quarter ended 30 <sup>th</sup> June 2014
<b>B</b>	<b>INVESTOR COMPLAINTS</b>	
	Pending at the beginning of the quarter	Nil
	Received during the quarter	9
	Disposed off during the quarter	9
	Remaining unresolved at the end of the quarter	Nil

**NOTES:**

1. The above results for the quarter ended 30<sup>th</sup> June 2014, as reviewed by the Audit Committee, were considered and approved by the Board of Directors at its meeting held on 11<sup>th</sup> August, 2014 and were subjected to 'limited review' by the Auditors.
2. The Company is primarily engaged in the manufacture of Active Pharmaceutical Ingredients and intermediates. Accordingly there are no reportable segments as per Accounting Standard 17 notified under the Companies Act, 1956.
3. As per Clause 41 of the listing agreement, the company has opted to publish quarterly unaudited standalone results and to publish consolidated results at the year end.


4. Details of forex gain/loss are given below:

	Quarter ended 30.06.2014	Quarter ended 31.03.2014	Quarter ended 30.06.2013	Year Ended 31.03.2014
	Rs. Lakhs	Rs. Lakhs	Rs. Lakhs	Rs. Lakhs
Forex gain/(loss)	135	(1800)	4253	5042

Forex gain has been included in Other Income and forex loss has been included in Other Expenses.

5. Figures for the previous year/period have been regrouped wherever necessary.
6. Figures in respect of the results for preceding quarter ended 31<sup>st</sup> March, 2014 are the balancing figures between audited figures in respect of the financial year ended 31<sup>st</sup> March, 2014 and the published year-to-date figures upto the third quarter ended 31<sup>st</sup> December, 2013.
7. As per the requirements of the Companies Act, 2013 ("the Act"), the company has computed depreciation on the basis of the estimated economic lives or useful lives of fixed assets in the manner prescribed in Schedule II of the Act. Consequently, depreciation for the quarter ended 30<sup>th</sup> June 2014 is higher by Rs.565 lakhs. Depreciation of Rs.1051 lakhs (net of deferred tax) on account of assets whose useful life is already exhausted as on 1<sup>st</sup> April 2014 has been adjusted to Retained Earnings.

Place: Hyderabad  
Date: 11<sup>th</sup> August, 2014



for Divi's Laboratories Limited

*Murali K. Divi*  
Dr. Murali K. Divi  
Chairman & Managing Director

*This is the statement referred to in our  
Limited Review Report dt. 11/08/2014*

*N. S. Khan*



## **DIVI'S LABORATORIES LIMITED**

**CIN No.L24110TG1990PLC011854**

**Divi Towers, Dharam Karan Road  
Hyderabad 500 016**

**Phone: 23786300 email: kishore@divislaboratories.com**

**PRESS RELEASE dated 11<sup>th</sup> August, 2014**


### **Divi's Labs earns a PAT of Rs. 168 crores for Q1 of FY15**

Divi's Laboratories has earned a Profit after Tax (PAT) of Rs.168 crores on a total income of Rs. 643 crores for the 1<sup>st</sup> quarter of the year 2014-15 on a Standalone basis. PAT for the corresponding quarter of the last year was Rs.175 crores on a total income of Rs.517 crores.

As per the requirements of the Companies Act 2013, the company provided Depreciation of Rs.33 crores for the quarter as against a depreciation of Rs.21 crores for the corresponding quarter of last year. Depreciation has been computed on the basis of the economic lives of fixed assets in the manner prescribed in Schedule II of the Act. Consequently, depreciation for the quarter ended 30<sup>th</sup> June 2014 is higher by Rs.6 crores as compared to the earlier procedure.

Tax provision for the current quarter came to Rs.46 crores as against a provision of Rs. 55 crores for the corresponding quarter of last year.

Forex gain for the current quarter amounted to Rs. 1 crore as against a gain of Rs. 43 crores during the corresponding quarter of the last year.



A handwritten signature in black ink, appearing to be 'Kishore', written over a horizontal line.



P.V.R.K. Nageswara Rao & Co.,  
Chartered Accountants

## LIMITED REVIEW REPORT

**TO  
THE BOARD OF DIRECTORS OF  
DIVI'S LABORATORIES LIMITED**

We have reviewed the accompanying statement of unaudited financial results of **DIVI'S LABORATORIES LIMITED** for the period ended **30<sup>th</sup> June, 2014** except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors / Committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with the accounting standards issued under the Companies (Accounting Standard) Rules, 2006 which continue to apply as per Section 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014, and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For P.V.R.K. NAGESWARA RAO & Co.,  
Chartered Accountants  
Firm's Registration Number: 002283S**

**HYDERABAD  
11.08.2014**

  
**N. ANKA RAO  
Partner  
Membership Number: 23939**

